1. Home
  2. Managing Adverse Effects of Incretin-Based Medications for Obesity

Managing Adverse Effects of Incretin-Based Medications for Obesity

Author/s: 
Robert F Kushner, Jaime P Almandoz, Domenica M Rubino
Date Added: 
August 1, 2025
Journal/Publication: 
JAMA Insights
Publication Date: 
July 29, 2025
URL: 
Managing Adverse Effects of Incretin-Based Medications for Obesity
Type: 
Meta-analyses, Reviews, and Guidelines
Format: 
Article
DOI (1): 
10.1001/jama.2025.11153
PMID (1): 
40728833
Keywords 
Semaglutide
tirzepatide
Incretins
diabetes mellitus
type 2 diabetes
Cardiovascular Diseases
overweight
MeSH 
Humans
Incretins
tirzepatide
semaglutide
diabetes mellitus, type 2
Glucagon-Like Peptide-1 Receptor Agonists
cardiovascular diseases
overweight
Gastric Inhibitory Polypeptide
renal insufficiency

RPR Commentary

Information on how to deal with the side effects of obesity medications. James W. Mold, MD, MPH

Abstract

This JAMA Insights explores optimal strategies for managing the adverse effects associated with incretin-based medications for obesity, including semaglutide and tirzepatide.